The Novel Angiotensin-(1–7) Analog, A-1317, Improves Insulin Resistance by Restoring Pancreatic β-Cell Functionality in Rats With Metabolic Syndrome
Open Access
- 24 August 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 11
Abstract
In previous studies we have shown that oral Ang-(1–7) has a beneficial therapeutic effect on cardiometabolic disturbances present in metabolic syndrome (MetS). Based on the fact that Ang-(1–7) acts through release of nitric oxide (NO), a new peptide, A-1317 was engineered adding the amino acid L-Arginine, the NO precursor, to the N-terminal portion of the Ang-(1–7). Therefore, in a single molecule the substrate and the activator of NO are combined. In the present study, we evaluated the effect of A-1317 oral treatment on liver-glucose metabolism in MetS induced by high fat (HF) diet in rats. Rats were subjected to control (AIN-93M, CT) or HF diets for 15 weeks to induce MetS and treated with A-1317, Ang-(1–7) included into hydroxypropyl-β-cyclodextrin (HPβCD) or empty HPβCD (E), in the last 7 weeks. At the end of 15 weeks, hemodynamic, biometric, and biochemical parameters, redox process, and qRT-PCR gene expression of NO synthase and RAS components were evaluated in the liver. HF/E rats increased body mass gain, adiposity index, despite the reduction in food intake, increased plasma leptin, total cholesterol, triglycerides, ALT, fasting blood glucose, OGTT and insulin, HOMA-IR and MAP and HR. Furthermore, the MetS rats presented increased in liver angiotensinogen, AT1R, ACE mRNA gene expression and concentration of MDA and carbonylated protein. Both Ang-(1–7) and A-1317 oral treatment in MetS rats reverted most of these alterations. However, A-1317 was more efficient in reducing body mass gain, ALT, AST, total cholesterol, insulin, fasting blood glucose, ameliorating β cell capacity by increasing HOMA-β and QUICKI, whereas Ang-(1–7) reduced HOMA-β and QUICKI. In addition, Ang-(1–7) increased Mas and AKT liver mRNA gene expression, while A-1317 increased both Mas and MRGD and AMPK liver mRNA gene expression, suggesting a distinct pathway of action of Ang-(1–7) and A-1317 in MetS rats. Taken together, our data showed that treatment with A-1317 was able to ameliorate MetS disorders and suggested that this effect was mainly via MRGD via activation of AMPK and increasing β cell function.Keywords
This publication has 45 references indexed in Scilit:
- Role of AMPK in pancreatic beta cell functionMolecular and Cellular Endocrinology, 2013
- Lipotoxicity: Effects of Dietary Saturated and Transfatty AcidsMediators of Inflammation, 2013
- IRE1-Dependent Activation of AMPK in Response to Nitric OxideMolecular and Cellular Biology, 2011
- Harmonizing the Metabolic SyndromeCirculation, 2009
- Chronic infusion of angiotensin-(1–7) improves insulin resistance and hypertension induced by a high-fructose diet in ratsAmerican Journal of Physiology-Endocrinology and Metabolism, 2009
- Molecular Mechanisms Involved in the Angiotensin-(1-7)/Mas Signaling Pathway in CardiomyocytesHypertension, 2008
- Angiotensin-(1-7) Through Receptor Mas Mediates Endothelial Nitric Oxide Synthase Activation via Akt-Dependent PathwaysHypertension, 2007
- The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteinsJournal of Cell Biology, 2004
- Characterization of a New Selective Antagonist for Angiotensin-(1–7), d -Pro 7 -Angiotensin-(1–7)Hypertension, 2003
- Gene Expression of Antioxidative Enzymes in the Human HeartCirculation, 2000